Capital Flow Monitor · Sponsors · CIK 1667699
Renibus Therapeutics, Inc.
181 GRAND AVE., SUITE 225, SOUTHLAKE, TX, 76092 · 386-527-1071
Pharmaceuticals · Corporation· inc. DELAWARE true
Fit score
—
Offering
$110.9M
Sold
$110.9M
% sold
100.0%
Investors
59
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-07-17 | D/A ·current | 506(b) | $110.9M | $110.9M | 100.0% | 59 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Carlos Guillem — Director, Southlake, TX
- D. Jeffrey Keyser — Executive Officer / Director, Southlake, TX
- Henrik Rasmussen — Director, Southlake, TX
- Bhupinder Singh — Executive Officer / Director, Southlake, TX
- Jamie Donadio — Executive Officer, Southlake, TX
Placement agents
- Salem Partners Llc · 0 RE raises
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.